Paul has over 20 years’ experience in the biopharmaceutical industry. He has over 15 years’ experience with Fusion Antibodies, initially in a variety of technical roles followed by eight years in business development, where he was responsible for developing Fusion Antibodies contract research services and seeking partners for the drug assets discovered and validated. Dr Kerr has a PhD from Queen’s University Belfast. Previous roles were developing monoclonal antibodies at The Queens University of Belfast and Veterinary Sciences Division, Stormont laboratory and ELISA development & testing services at Campden BRI, Chipping Campden, Gloucestershire, UK. Dr Kerr joined Fusion Antibodies as a Director and was appointed as Managing Director in 2011.